Trials / Conditions / Stage IIIA Rectal Cancer

Stage IIIA Rectal Cancer

23 registered clinical trials studyying Stage IIIA Rectal Cancer.

Status	Trial	Sponsor	Phase
Terminated	Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Can NCT04044430	University of California, San Francisco	Phase 1
Completed	Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190	Stanford University	N/A
Withdrawn	Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-I NCT02287727	Roswell Park Cancer Institute	Phase 2
Completed	CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surg NCT02232152	Wake Forest University Health Sciences	Phase 1
Completed	Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer NCT02270606	Virginia Commonwealth University	Phase 1
Completed	Programs to Support You During Chemotherapy (Pro-You) NCT02148406	Vanderbilt-Ingram Cancer Center	N/A
Completed	Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Adv NCT02132858	Fox Chase Cancer Center	—
Terminated	Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemot NCT01934179	Fox Chase Cancer Center	—
Completed	Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointe NCT01846520	City of Hope Medical Center	N/A
Unknown	Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage NCT01871571	University of Southern California	Phase 2
Completed	PET-MRI in Diagnosing Patients With Colon or Rectal Cancer NCT01807117	Case Comprehensive Cancer Center	N/A
Completed	Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or NCT01802320	National Cancer Institute (NCI)	Phase 2
Completed	Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorect NCT01726296	Fox Chase Cancer Center	N/A
Completed	Survivorship Care Planning in Patients With Colorectal or Non-Small Cell Lung Cancer NCT01741636	City of Hope Medical Center	N/A
Completed	Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal C NCT01740648	Ohio State University Comprehensive Cancer Center	Phase 1
Completed	Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointest NCT01643499	University of Chicago	Phase 1
Completed	Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234	National Cancer Institute (NCI)	Phase 1
Completed	Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma NCT00754494	National Cancer Institute (NCI)	Phase 2
Completed	SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer NCT00103311	National Cancer Institute (NCI)	Phase 2
Completed	A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, an NCT00060411	National Cancer Institute (NCI)	Phase 1
Completed	Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer NCT00005036	National Cancer Institute (NCI)	Phase 3
Completed	Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer NCT00003799	National Cancer Institute (NCI)	Phase 1
Withdrawn	Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic P NCT02575508	Roswell Park Cancer Institute	Phase 1 / Phase 2